At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 37 enrolled
Drug / intervention
Pentoxifylline +1 moredrug
Likely dose
Pentoxifylline 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Pentoxifylline on PAI-1 in an Obese Population
In Brief
A Phase 4 clinical trial evaluating Pentoxifylline and Placebo for Obesity. Completed, enrolled 37 participants across 1 site.
Detailed Summary
PAI-1 is elevated in obese individuals. TNF-alpha, an inflammatory mediator is believed to play a role in obesity mediated elevations in PAI-1 levels. TNF-alpha blockade with antibodies and the drug pentoxifylline have been shown to lower PAI-1 levels in animal models. This study tests the hypothesis that pentoxifylline will lower PAI-1 levels in human subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2003
First PostedOct 2008
Primary CompletionMay 2009
Study CompletionJun 2009
TodayJul 2026
First PostedOct 10, 2008
Enrollment StartMay 1, 2003
Primary CompletionMay 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 17.7 years ago
Interventions
Pentoxifyllinedrug
400mg PO TID x 8 weeks
Placebodrug
PO TID x 8 weeks